Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 16, 2016 08:00 ET | Source: Pluri Inc.

National Institutes of Health’s NIAID Initiating Dose Evaluation Studies in Animal Models of Pluristem’s PLX-R18 in the Treatment of Acute Radiation Syndrome

HAIFA, Israel, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that the...
February 10, 2016 08:00 ET | Source: Pluri Inc.

Pluristem Reports Second Quarter Fiscal 2016 Financial Highlights and Clinical Development Update

HAIFA, Israel, Feb. 10, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today reported financial...
January 26, 2016 03:00 ET | Source: Pluri Inc.

Pluristem to Present at Bio CEO & Investor Conference in New York City on February 8, 2016

HAIFA, Israel, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that Dr. Karine...
January 12, 2016 03:00 ET | Source: Pluri Inc.

Pluristem Receives U.S. FDA Clearance to Initiate Clinical Trial of PLX-R18 to Treat Insufficient Hematopoietic Recovery Following Bone Marrow Transplant

Phase I, open-label trial will allow for interim data analysisPLX-R18 could potentially treat a broad range of hematologic indications Pluristem will pursue early market access for PLX-R18 in the...
January 06, 2016 05:00 ET | Source: Pluri Inc.

New Peer Reviewed Article Describes Mechanism of Action of PLX-PAD in Ameliorating Preeclampsia and Indicates Their Superiority Over Other Cells

- First published study comparing therapeutic outcome of placenta-derived cells as compared to cells derived from bone marrow or fat tissue - Data describes the mechanism of action of PLX-PAD cells...
December 31, 2015 07:00 ET | Source: Pluri Inc.

U.S. Food & Drug Administration Grants Orphan Drug Designation to Pluristem’s PLX-PAD Cells for Treatment of Severe Preeclampsia

HAIFA, Israel, Dec. 31, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that the U.S....
December 21, 2015 02:00 ET | Source: Pluri Inc.

Pluristem Reaches Agreement With Japan's PMDA on Protocol for Final Trial Targeting Market Entry Via Accelerated Pathway

The agreement is expected to accelerate discussions with potential Japanese partnersThe study will include 75 patients and a 9 month follow-up HAIFA, Israel, Dec. 21, 2015 (GLOBE NEWSWIRE) --...
December 17, 2015 03:00 ET | Source: Pluri Inc.

Pluristem to Present at Phacilitate Cell & Gene Therapy World Conference in Washington DC on January 25-26, 2016

HAIFA, Israel, Dec. 17, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that the...
December 08, 2015 09:34 ET | Source: Pluri Inc.

Pluristem and United Therapeutics End Licensing Agreement; Report Positive Data in Pulmonary Arterial Hypertension

Clinical study is ongoing and encouraging data reported for the first cohortPluristem regains full rights with benefit of human clinical data for the indication & IV administration of PLX cells ...
December 03, 2015 01:30 ET | Source: Pluri Inc.

Pluristem Signs MOU for Collaboration With Fukushima Medical University to Study PLX-R18 in Acute Radiation Syndrome

HAIFA, Israel, Dec. 03, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that it has...